Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279816 | 0.95 | MAPKAPK5 (0.55) | MAPKAPK5JAK2JAK1TYK2JAK3 | |
| SCHEMBL275414 | 0.95 | MAPKAPK5 (0.55) | MAPKAPK5JAK2JAK1TYK2JAK3 | |
| SCHEMBL279482 | 0.87 | MAPKAPK5 (0.62) | MAPKAPK5TTKFLT3 | |
| SCHEMBL274996 | 0.85 | JAK2 (0.44) | MAPKAPK5JAK2JAK1TYK2JAK3 | |
| SCHEMBL274878 | 0.85 | MAPKAPK5 (0.61) | MAPKAPK5TTK | |
| SCHEMBL279480 | 0.84 | MAPKAPK5 (0.60) | MAPKAPK5TTK | |
| SCHEMBL274317 | 0.81 | RIPK1 (0.43) | MAPKAPK5JAK2JAK1TYK2JAK3 | |
| SCHEMBL279710 | 0.81 | RIPK1 (0.43) | MAPKAPK5JAK2JAK1TYK2JAK3 | |
| SCHEMBL279683 | 0.77 | MAPKAPK5 (0.60) | MAPKAPK5TTK | |
| SCHEMBL13857417 | 0.76 | MAPKAPK5 (0.58) | MAPKAPK5TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | NOD1, TNF, NOD2 | MAPKAPK5 1247/4885JAK2 1348/4885JAK1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.